Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

作者：Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, Tao Sun, Wěi Li, Quchang Ouyang, Xichun Hu, Ying Cheng, Min Yan, Yueyin Pan, Yuee Teng, Xi Yan, Ying Wang, Weimin Xie, Xiaohua Zeng, Xiaojia Wang, Chang-Lu Hu, Cuizhi Geng, Hongwei Zhang, Wenxin Li, Xinhong Wu, Jincai Zhong, Jingwei Xu, Yanxia Shi, Wenhua Wei, Nayima Bayaxi, Xiaoyu Zhu, Binghe Xu · 发表于：The Lancet Oncology · 年份：2023 · DOI：10.1016/s1470-2045(23)00172-9 · 被引用次数：103 · 研究领域：Advanced Breast Cancer Therapies、Cancer-related Molecular Pathways、Estrogen and related hormone effects